BioNTech faces a whistleblower lawsuit over pancreatic cancer trial misconduct just as its founder separation deal nears closure, adding uncertainty to its oncology pivot.
BioNTech is navigating a period of profound transformation, juggling a leadership restructuring with a legal challenge that threatens to unsettle investors. Just days before a landmark founder separation deal is set to close, a former clinical trials manager has filed a whistleblower lawsuit alleging serious misconduct in two of the company’s most important pancreatic cancer studies.
Angela Carter, who oversaw clinical operations until recently, lodged the complaint at a district court in North Carolina in late June 2026. Court documents claim she flagged instances of incorrect dosing, missing lab results, and deficient record-keeping in the trials. After raising these concerns internally, Carter says she was dismissed. BioNTech has formally rejected the allegations as baseless and is fighting the suit.
The company’s oncology pipeline is the linchpin of its post-Covid strategy, making any suggestion of flawed trial execution a sensitive issue for shareholders. Flawless data is essential for regulatory approval, and a protracted legal dispute could slow the timeline for advancing these candidates.
Meanwhile, the corporate overhaul accelerates. Ugur Sahin and Özlem Türeci, the scientists who built BioNTech, are leaving the executive board to set up a new mRNA-focused venture. The...
TikToker Camilla Alhassan Jailed 1 Year Over False Claims About Prez Mahama BBC CNN DW CGTN NBC ABC ALJazeera France24 JoyNews CitiTV Net2TV TV3 UTV DelayTV KofiTV MagrahebTV MGTV OTHERS | Movies...